Glumetza is owned by Santarus Inc.
Glumetza contains Metformin Hydrochloride.
Glumetza has a total of 2 drug patents out of which 0 drug patents have expired.
Glumetza was authorised for market use on 03 June, 2005.
Glumetza is available in tablet, extended release;oral dosage forms.
The generics of Glumetza are possible to be released after 23 March, 2025.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7780987 | SANTARUS INC | Controlled release dosage forms |
Mar, 2025
(2 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8323692 | SANTARUS INC | Controlled release dosage forms |
Mar, 2023
(a month from now) |
Drugs and Companies using METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 03 June, 2005
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic